Impact of ursodeoxycholic acid therapy in autoimmune liver disease patients with COVID-19 and its clinical prognosis

IF 3.5 Q1 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH

Biosafety and Health Pub Date : 2024-06-01 DOI:10.1016/j.bsheal.2024.04.004

Minghui Li , Weihua Cao , Tingting Jiang , Wen Deng , Shiyu Wang , Shuling Wu , Lu Zhang , Yao Lu , Min Chang , Ruyu Liu , Xiaoyan Ding , Ge Shen , Yuanjiao Gao , Hongxiao Hao , Xiaoxue Chen , Leiping Hu , Mengjiao Xu , Yuyong Jiang , Wei Yi , Yao Xie , Rui Song

{"title":"Impact of ursodeoxycholic acid therapy in autoimmune liver disease patients with COVID-19 and its clinical prognosis","authors":"Minghui Li , Weihua Cao , Tingting Jiang , Wen Deng , Shiyu Wang , Shuling Wu , Lu Zhang , Yao Lu , Min Chang , Ruyu Liu , Xiaoyan Ding , Ge Shen , Yuanjiao Gao , Hongxiao Hao , Xiaoxue Chen , Leiping Hu , Mengjiao Xu , Yuyong Jiang , Wei Yi , Yao Xie , Rui Song","doi":"10.1016/j.bsheal.2024.04.004","DOIUrl":null,"url":null,"abstract":"<div>To explore the impact of ursodeoxycholic acid (UDCA) on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and clinical outcomes in patients with autoimmune liver disease (AILD). Patients diagnosed with AILD were enrolled and divided into a UDCA group and a non-UDCA group based on whether they received UDCA treatment. Relevant data were collected regarding AILD diagnosis, treatment, biochemical indicators, and imaging examination. The incidence of SARS-CoV-2 infection and the prognosis of AILD patients were observed. A total of 1,138 patients completed follow-up. The usage rate of hormone (P = 0.003) and immunosuppressant (P = 0.001) used for treating AILD in the non-UDCA group was markedly lower than in the UDCA group. The UDCA usage rate was markedly lower in SARS-CoV-2 infected patients than in uninfected patients (P = 0.003). The rate of SARS-CoV-2 infection in the non-UDCA group was significantly higher than in the UDCA group (P = 0.018). Logistic regression analysis showed that UDCA use (P = 0.003) was correlated to a lower incidence of SARS-CoV-2, while immunosuppressant use (P = 0.017) increased the incidence. Recovery time from SARS-CoV-2 infection was markedly longer for those receiving UDCA treatment than those in the non-UDCA group (P = 0.018). UDCA is associated with low SARS-CoV-2 incidence in AILD patients, while immunosuppressant increases its incidence instead. Patients receiving UDCA treatment have a longer recovery time after being infected.</div>","PeriodicalId":36178,"journal":{"name":"Biosafety and Health","volume":null,"pages":null},"PeriodicalIF":3.5000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590053624000545/pdfft?md5=bd6ab21d4a00accdd4ec3b047274df81&pid=1-s2.0-S2590053624000545-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biosafety and Health","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2590053624000545","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}

引用次数: 0

Abstract

To explore the impact of ursodeoxycholic acid (UDCA) on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and clinical outcomes in patients with autoimmune liver disease (AILD). Patients diagnosed with AILD were enrolled and divided into a UDCA group and a non-UDCA group based on whether they received UDCA treatment. Relevant data were collected regarding AILD diagnosis, treatment, biochemical indicators, and imaging examination. The incidence of SARS-CoV-2 infection and the prognosis of AILD patients were observed. A total of 1,138 patients completed follow-up. The usage rate of hormone (P = 0.003) and immunosuppressant (P = 0.001) used for treating AILD in the non-UDCA group was markedly lower than in the UDCA group. The UDCA usage rate was markedly lower in SARS-CoV-2 infected patients than in uninfected patients (P = 0.003). The rate of SARS-CoV-2 infection in the non-UDCA group was significantly higher than in the UDCA group (P = 0.018). Logistic regression analysis showed that UDCA use (P = 0.003) was correlated to a lower incidence of SARS-CoV-2, while immunosuppressant use (P = 0.017) increased the incidence. Recovery time from SARS-CoV-2 infection was markedly longer for those receiving UDCA treatment than those in the non-UDCA group (P = 0.018). UDCA is associated with low SARS-CoV-2 incidence in AILD patients, while immunosuppressant increases its incidence instead. Patients receiving UDCA treatment have a longer recovery time after being infected.

查看原文本刊更多论文

熊去氧胆酸治疗对 COVID-19 自身免疫性肝病患者的影响及其临床预后

目的：探讨熊去氧胆酸（UDCA）对自身免疫性肝病（AILD）患者严重急性呼吸系统综合征冠状病毒2（SARS-CoV-2）感染和临床预后的影响。研究人员招募了确诊为自身免疫性肝病（AILD）的患者，并根据他们是否接受 UDCA 治疗将其分为 UDCA 组和非 UDCA 组。收集了有关 AILD 诊断、治疗、生化指标和影像学检查的相关数据。观察 AILD 患者的 SARS-CoV-2 感染率和预后。共有 1 138 名患者完成了随访。非 UDCA 组用于治疗 AILD 的激素（P = 0.003）和免疫抑制剂（P = 0.001）的使用率明显低于 UDCA 组。感染 SARS-CoV-2 的患者使用 UDCA 的比例明显低于未感染患者（P = 0.003）。非 UDCA 组的 SARS-CoV-2 感染率明显高于 UDCA 组（P = 0.018）。逻辑回归分析显示，使用 UDCA（P = 0.003）与较低的 SARS-CoV-2 感染率相关，而使用免疫抑制剂（P = 0.017）则会增加感染率。接受 UDCA 治疗的患者从 SARS-CoV-2 感染中恢复的时间明显长于未接受 UDCA 治疗的患者（P = 0.018）。UDCA 可降低 AILD 患者的 SARS-CoV-2 感染率，而免疫抑制剂反而会增加感染率。接受 UDCA 治疗的患者在感染后的恢复时间更长。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊